Psyence Biomedical Ltd. Common Shares (PBM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $6.50 (+2.85%), Market cap $0.01B, 52-week low–high $0.63 ~ $11.50.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted ps
Financial statements, price targets, institutional (13F) holdings and related news for Psyence Biomedical Ltd. Common Shares are updated in real time on BlackAll Trade.
Psyence Biomedical Ltd. Common Shares trades at $6.50 (+2.85%). Real-time quotes and charts are available on BlackAll Trade.
Psyence Biomedical Ltd. Common Shares has a market cap of about $0.01B.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with a